Tackling antibiotic resistance

  title={Tackling antibiotic resistance},
  author={Karen Bush and Patrice Courvalin and Gautam Dantas and Julian E. Davies and Barry I. Eisenstein and Pentti Huovinen and George A. Jacoby and Roy Kishony and Barry N. Kreiswirth and Elizabeth Kutter and Stephen A. Lerner and Stuart B. Levy and Kim Lewis and Olga Lomovskaya and Jeffrey H. Miller and Shahriar Mobashery and Laura J. V. Piddock and Steven J. Projan and Christopher M Thomas and Alexander Tomasz and Paul M. Tulkens and Timothy Rutland Walsh and James D. Watson and Jan A. Witkowski and Wolfgang Witte and Gerry D Wright and Pamela J. Yeh and Helen I. Zgurskaya},
  journal={Nature Reviews Microbiology},
The development and spread of antibiotic resistance in bacteria is a universal threat to both humans and animals that is generally not preventable but can nevertheless be controlled, and it must be tackled in the most effective ways possible. To explore how the problem of antibiotic resistance might best be addressed, a group of 30 scientists from academia and industry gathered at the Banbury Conference Centre in Cold Spring Harbor, New York, USA, from 16 to 18 May 2011. From these discussions… 

Why is antibiotic resistance a deadly emerging disease?

  • P. Courvalin
  • Biology
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2016

Resistance is futile: the bacteriocin model for addressing the antibiotic resistance challenge.

A new paradigm in antibiotic discovery and development is proposed, one that applies ecological and evolutionary theory to design antimicrobial drugs that are more difficult and/or more costly to resist.

Introduction to antibiotic resistance.

The absolute number of new antibiotics licensed has declined especially for Gram-negative multidrug-resistant pathogens, and the reasons for this failure are presented here: market issues, big pharma changes, regulatory constraints, difficulties in finding drugable targets and suitable compounds worthy of full development.

Antimicrobial resistance: a complex issue.

Reducing the use of antimicrobial drugs is one way to control antimicrobial resistance; however, a full set of measures needs to be implemented to achieve this aim.

The Whys and Wherefores of Antibiotic Resistance.

Understanding of these processes, paired with sequence information from terrestrial bacterial populations, indicates that there is no shortage of novel natural products that could be developed into new medicines, despite the development and rapid dissemination of antibiotic-resistant bacterial pathogens.

Overview of strategies for overcoming the challenge of antimicrobial resistance

Evidence of progress with antibiotic stewardship in Europe and nationally in Scotland is reviewed to ensure effective treatment for patients with bacterial infection and provide convincing evidence and information to educate and support professionals and patients to reduce unnecessary use and minimize collateral damage.

Bacterial Resistance Against Antibiotics

There is an urgent necessity to discover more antibiotics to combat the bacterial infections, and there is a need to advance the microbial informatics, particularly the development of databases and tools.

Bacteriophage Therapy: An Unforgetten Source of Cure

In this rediscovery process in area of infectious diseases and clinical microbiology, it is important to consider the interesting history of phage therapy, the reasons for abandonment, the advantages/ disadvantages over antibiotics, and the concerns about deployment in clinical use.


Although it seems not easy to cope with the global and complex ABR problem, there is one approach, bacteriophage therapy, that could be an essential part in the process of resolving this antibiotic crisis.



Targeting virulence to prevent infection: to kill or not to kill?

The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.

The time has come for a global commitment to develop new antibacterial drugs. Current data document the impending disaster due to the confluence of decreasing investment in antibacterial drug

Drugs for bad bugs: confronting the challenges of antibacterial discovery

The experience of evaluating more than 300 genes and 70 high-throughput screening campaigns over a period of 7 years is shared, and what is learned is looked at and how that has influenced GlaxoSmithKline's antibacterials strategy going forward.

Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship.

  • R. RobertsB. Hota R. Weinstein
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2009
Data from this analysis could form the basis for a more comprehensive evaluation of the cost of resistance and the potential economic benefits of prevention programs.

Development of an educational resource on microbes, hygiene and prudent antibiotic use for junior and senior school children.

The process involved during the development of a pan-European educational resource is outlined, and the final pack layout is identified, based on feedback from teacher focus groups, student questionnaires and European partner discussions.

Human nutrition, the gut microbiome and the immune system

Understanding how the diet and nutritional status influence the composition and dynamic operations of the authors' gut microbial communities, and the innate and adaptive arms of the immune system, should help to address several pressing global health problems.

Emerging viruses, emerging threat.

Marine natural products.

Development of daptomycin for gram-positive infections.

implications for antibiotic stewardship

  • Clin. Inf. Dis. 49, 1175–1184
  • 2009